These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. Vella S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511 [TBL] [Abstract][Full Text] [Related]
29. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. Dollé V; Fan E; Nguyen CH; Aubertin AM; Kirn A; Andreola ML; Jamieson G; Tarrago-Litvak L; Bisagni E J Med Chem; 1995 Nov; 38(23):4679-86. PubMed ID: 7473595 [TBL] [Abstract][Full Text] [Related]
30. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. Staszewski S; Massari FE; Kober A; Göhler R; Durr S; Anderson KW; Schneider CL; Waterbury JA; Bakshi KK; Taylor VI J Infect Dis; 1995 May; 171(5):1159-65. PubMed ID: 7538547 [TBL] [Abstract][Full Text] [Related]
32. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. Imamichi T; Murphy MA; Imamichi H; Lane HC J Virol; 2001 Apr; 75(8):3988-92. PubMed ID: 11264389 [TBL] [Abstract][Full Text] [Related]
33. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. de Clercq E Med Res Rev; 1996 Mar; 16(2):125-57. PubMed ID: 8656777 [No Abstract] [Full Text] [Related]
34. Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. Kashiwada Y; Hashimoto F; Cosentino LM; Chen CH; Garrett PE; Lee KH J Med Chem; 1996 Mar; 39(5):1016-7. PubMed ID: 8676334 [No Abstract] [Full Text] [Related]
35. Molecular aspect of HIV-1 resistance to zidovudine and its reversal. Camsonne R; Bigot MC; Bustany P; Pottier D; Vergnaud M Trends Pharmacol Sci; 1994 May; 15(5):137-8. PubMed ID: 7538701 [No Abstract] [Full Text] [Related]
36. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Maass G; Immendoerfer U; Koenig B; Leser U; Mueller B; Goody R; Pfaff E Antimicrob Agents Chemother; 1993 Dec; 37(12):2612-7. PubMed ID: 7509144 [TBL] [Abstract][Full Text] [Related]
37. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors. Goldman ME; O'Brien JA; Ruffing TL; Schleif WA; Sardana VV; Byrnes VW; Condra JH; Hoffman JM; Emini EA Antimicrob Agents Chemother; 1993 May; 37(5):947-9. PubMed ID: 7685996 [TBL] [Abstract][Full Text] [Related]
38. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Ichimura H; Levy JA Virology; 1995 Aug; 211(2):554-60. PubMed ID: 7544050 [TBL] [Abstract][Full Text] [Related]
39. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Naeger LK; Margot NA; Miller MD Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416 [TBL] [Abstract][Full Text] [Related]
40. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Balzarini J; Weeger M; Camarasa MJ; De Clercq E; Uberla K Biochem Biophys Res Commun; 1995 Jun; 211(3):850-6. PubMed ID: 7541200 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]